Skip to main content
    A

    Aprea Therapeutics Inc (APRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.41
    -0.01 (-2.38%)

    Market Cap: $5.91M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Aprea Therapeutics Inc (APRE) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Aprea Therapeutics are Processa Pharmaceuticals (PCSA), Tempest Therapeutics (TPST) and Traws Pharma (TRAW). By market cap, Aprea Therapeutics ranks 7th of the 13 companies on this page; Phio Pharmaceuticals (PHIO) is the largest at $9.21M.

    Peer Comparison

    APRE's revenue growth of -98.4% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Aprea Therapeutics (APRE)$5.91MN/AN/A0.0%N/A-98.4%0.00%
    Processa Pharmaceuticals Inc (PCSA)$5.20MN/AN/A0.0%N/A0.0%0.00%
    Tempest Therapeutics Inc (TPST)$7.64MN/AN/A0.0%-783.6%0.0%0.00%
    Traws Pharma Inc (TRAW)$3.86MN/AN/A0.0%N/A-100.0%0.00%
    Azitra Inc (AZTR)$3.69MN/AN/A0.0%N/A-100.0%0.00%
    Alaunos Therapeutics Inc (TCRT)$6.86MN/AN/A0.0%N/A-25.0%0.00%
    Lantern Pharma Inc (LTRN)$6.47MN/AN/A0.0%N/A0.0%0.00%
    Theriva Biologics Inc. (TOVX)$6.61MN/A21.5x0.0%-52.3%0.0%0.00%
    Phio Pharmaceuticals Corp (PHIO)$9.21MN/AN/A0.0%N/A0.0%0.00%
    Moleculin Biotech Inc (MBRX)$8.02MN/AN/A0.0%N/A0.0%0.00%
    PharmaCyte Biotech Inc (PMCB)$3.77MN/AN/A0.0%N/A0.0%0.00%
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)$4.02MN/AN/A0.0%-247.2%0.0%0.00%
    Pulmatrix Inc (PULM)$4.71MN/AN/A0.0%N/A-99.9%0.00%
    Peer median$5.84MN/A21.5x0.0%-247.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Aprea Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Processa Pharmaceuticals Inc (PCSA)
    Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients...
    PCSA competitors
    Tempest Therapeutics Inc (TPST)
    Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated...
    TPST competitors
    Traws Pharma Inc (TRAW)
    Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.
    TRAW competitors
    Azitra Inc (AZTR)
    Azitra Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live...
    AZTR competitors
    Alaunos Therapeutics Inc (TCRT)
    Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring...
    TCRT competitors
    Lantern Pharma Inc (LTRN)
    Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics...
    LTRN competitors
    Theriva Biologics Inc. (TOVX)
    Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need.
    TOVX competitors
    Phio Pharmaceuticals Corp (PHIO)
    Phio Pharmaceuticals Corp. The company is headquartered in Marlborough, Massachusetts.
    PHIO competitors
    Moleculin Biotech Inc (MBRX)
    Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant...
    MBRX competitors
    PharmaCyte Biotech Inc (PMCB)
    PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United...
    PMCB competitors
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)
    Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California.
    LIMN competitors
    Pulmatrix Inc (PULM)
    Pulmatrix, Inc., a clinical-stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases...
    PULM competitors

    Frequently Asked Questions About APRE

    Who are Aprea Therapeutics' main competitors?

    The companies most similar to Aprea Therapeutics include Processa Pharmaceuticals (PCSA), Tempest Therapeutics (TPST), Traws Pharma (TRAW), Azitra (AZTR) and Alaunos Therapeutics (TCRT), listed from the closest match.

    Who is Aprea Therapeutics' biggest competitor?

    Phio Pharmaceuticals (PHIO) is the largest of the similar companies at $9.21M; Processa Pharmaceuticals (PCSA) is the closest match by business profile, size, sector and industry.

    How does APRE stock compare with its competitors?

    APRE's net margin is 0.0% against a peer median of 0.0%.

    Which of Aprea Therapeutics' competitors pays a higher dividend?

    Aprea Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Aprea Therapeutics bigger than its competitors?

    No. Aprea Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Phio Pharmaceuticals (PHIO) at $9.21M.